Europe Diabetic Foot Ulcer Treatment Market Size, Trends, Share, Growth | Report 2022-2030
The Europe diabetic foot ulcer treatment market size was estimated at around USD 1.52 billion in 2021 and it is projected to hit around USD 2.4 billion by 2030, growing at a CAGR of 5.21% from 2022 to 2030
Report Highlights
Diabetes is one of the major causes of amputation, blindness, stroke, end-stage renal failure, kidney failure, and heart attacks in this region. According to the International Diabetes Federation, ~66 million people were suffering from diabetes in Europe in 2017. The number is expected to increase to ~81 million by 2045. The mortality rate associated with DFU is ~5% in the first 12 months and increases up to 42% by the end of 5 years. Many adjuvant therapies, such as nonsurgical debridement agents, dressings & topical agents, oxygen therapies, negative pressure wound therapy, acellular bioproducts, human growth factors, energy-based therapies, and systemic therapies, are said to effectively improve and cure DFU.
Recent studies suggest that the inhibition of detrimental proteinase MMP-9 enzyme, allows the body to heal the wound at a quicker rate. The biologics segment held the largest revenue share in 2021 and is projected to expand further at the fastest CAGR during the forecast period. Biologics include growth factors, such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), stem cells, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation & circulation, and repair lost tissues. Therefore, they are increasingly being used for the management of wounds in different stages and are considered to be ideal for DFU treatment. Wound care dressings held the second-largest revenue share, followed by therapy devices and antibiotic medications, in 2021. Industry players are constantly developing new and improved products to ensure quicker healing time for DFU.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 1.52 billion |
| Revenue Forecast by 2030 | USD 2.4 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.21% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Treatment, ulcer type, Region |
| Companies Covered | ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast Corp.; Smith & Nephew Plc.; B Braun Melsungen AG; Medline Industries Inc.; Organogenesis, Inc.; Molnlycke Health Care AB; Medtronic |
Treatment Insights
The biologics segment dominated the regional market and accounted for the largest share of 34.7% of the overall revenue in 2021 and the segment is projected to expand further at the fastest CAGR during the forecast period. Biologics include growth factors, such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), among others], stem cells, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation & circulation, and repair lost tissues. Therefore, they are increasingly being used for the management of wounds in different stages and are considered to be ideal for DFU treatment. Wound care dressings held the second-largest share of the global revenue, followed by therapy devices and antibiotic medications, in 2021.
Wound care is further segmented into alginate dressings, hydro fiber dressings, foam dressings, film dressings, hydrocolloid dressings, surgical dressings, and hydrogel dressing. Foam dressing held the largest share in 2021. These dressings have been designed to absorb exudate and maintain moisture on the wound surface. Polyurethane foam dressings are applied directly or with an antimicrobial layer on the affected area and are then wrapped with a gauze or a bandage to provide compression. Alginate dressing, on the other hand, will register the highest CAGR from 2022 to 2030 due to the increasing use of alginate dressings in the treatment of DFUs. Alginate dressings are highly absorbent and help in maintaining a moist wound healing environment.
Ulcer Type Insights
The neuro-ischemic ulcers segment dominated the industry in 2021 and accounted for the largest share of more than 52.03% of the overall revenue, followed by the neuropathic and ischemic ulcer segments. The growth of this segment can be attributed to the number of risks associated with neuro-ischemic ulcers, such as infection, amputation, and death. Neuropathic ulcer affects nearly 35% of all ulcers, however, neuro-ischemia affects ~50% of the diabetic population. Sensorimotor and sympathetic diabetic neuropathy are major risk factors for DFU. Sensory neuropathy leads to loss of pain, pressure, and temperature sensation. In this case, trauma, or minor ulceration is perceived less or not at all. Motor neuropathy leads to muscle weakness and atrophy of the lower foot and ankle resulting in abnormal loading of the plantar aspect of the foot.
Foot deformities, such as hammer toes and claw foot, develop secondary to motor neuropathy, leading to focal areas of increased pressure and the formation of calluses and ulcers. Sympathetic neuropathy results in reduced sweating, skin dryness with cracks and fissures, and increased blood flow to the foot with arteriovenous shunting. Hyperbaric oxygen therapy and sucrose octa sulfate dressing, are among the few highly researched treatments for neuro ischemic ulcers. Contact cast is considered the most effective option for treating neuro ischemic ulcers. Increased research and clinical studies are said to further enhance the growth of this segment. Treatment of DFU costs around, ~USD 779.50 million per annum in the U.K. and ~USD 10.21 billion per annum across Europe.
Regional Insights
Germany dominated the overall industry in 2021 and accounted for the largest share of 28.16% of the total revenue. This growth was attributed to the presence of the highest diabetic patient population in the country. Globally, an estimated 463 million adults have diabetes out of which, 59 million are in Europe alone. In 2019, the diabetic prevalence rate had reached 15.3%, up from 12.2% in 2017. This leads to a total of ~9.5 million population suffering from diabetes out of which, 4.5 million cases go undiagnosed. Yearly ~6% of pregnant women in Germany suffer from gestational diabetes. The rising incidence of diabetes in this country has led to a sharp rise in the treatment for diabetic foot ulcers, leading to industry growth.
Other countries include the U.K., Italy, Spain, France, and Poland. According to the international diabetes federation, there were 747,600 cases of diabetes in Germany and 3.8 million people in the U.K. Around 10% of these diabetes patients develops foot ulcer in their lifetime. More than 7,000 diabetes amputation cases are reported in the country per year. Among diabetes hospital admissions in the U.K., 8.8% were related to amputation and ulcers. Around 25% of people with diabetes experience foot ulceration during their lifetime. Every year more than 22,000 people with diabetes mellitus lose a leg as a result of amputation.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Europe Diabetic Foot Ulcer Treatment Market
5.1. COVID-19 Landscape: Europe Diabetic Foot Ulcer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Europe Diabetic Foot Ulcer Treatment Market, By Treatment
8.1. Europe Diabetic Foot Ulcer Treatment Market, by Treatment, 2022-2030
8.1.1. Wound Care Dressings
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Biologics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Therapy Devices
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antibiotic Medications
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Europe Diabetic Foot Ulcer Treatment Market, By Ulcer Type
9.1. Europe Diabetic Foot Ulcer Treatment Market, by Ulcer Type, 2022-2030
9.1.1. Neuropathic Ulcers
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ischemic Ulcers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Neuro-ischemic Ulcers
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Europe Diabetic Foot Ulcer Treatment Market, Regional Estimates and Trend Forecast
10.1. Europe
10.1.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.2. Market Revenue and Forecast, by Ulcer Type (2017-2030)
10.1.3. UK
10.1.3.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Ulcer Type (2017-2030)
10.1.4. Germany
10.1.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Ulcer Type (2017-2030)
10.1.5. France
10.1.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Ulcer Type (2017-2030)
10.1.6. Rest of Europe
10.1.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.6.2. Market Revenue and Forecast, by Ulcer Type (2017-2030)
Chapter 11. Company Profiles
11.1. ConvaTec, Inc.
11.1.1. Company Overview
11.1.2. Treatment Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Acelity L.P., Inc.
11.2.1. Company Overview
11.2.2. Treatment Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. 3M Healthcare
11.3.1. Company Overview
11.3.2. Treatment Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Coloplast Corp.
11.4.1. Company Overview
11.4.2. Treatment Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Smith & Nephew Plc
11.5.1. Company Overview
11.5.2. Treatment Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. B Braun Melsungen AG
11.6.1. Company Overview
11.6.2. Treatment Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medline Industries, Inc.
11.7.1. Company Overview
11.7.2. Treatment Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Organogenesis, Inc.
11.8.1. Company Overview
11.8.2. Treatment Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Molnlycke Health Care AB
11.9.1. Company Overview
11.9.2. Treatment Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Medtronic
11.10.1. Company Overview
11.10.2. Treatment Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers